December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Effectiveness of Bimatoprost (LUMIGAN) as Adjunctive Therapy with Topical Beta-blockers in Patients with Glaucoma or Ocular Hypertension: A 3-Month, Multi-center, Double-masked, Randomized, Vehicle-controlled Trial with Double-masked Extension of Bimatoprost Treatment to 1 Year
Author Affiliations & Notes
  • S Melamed
    Glaucoma Unit Dept Ophthal Goldschleger Eye Institute Tel-Hashomer Israel
  • I Bossawska
    Allergan Inc Irvine CA
  • C LarochBimatoprost Adjunctive to Timolol Study Group
    Allergan Inc Irvine CA
  • Footnotes
    Commercial Relationships    S. Melamed, Allergan, Inc. R; I. Bossawska, Allergan, Inc. E; C. Laroch, Allergan, Inc. E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1068. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S Melamed, I Bossawska, C LarochBimatoprost Adjunctive to Timolol Study Group; Effectiveness of Bimatoprost (LUMIGAN) as Adjunctive Therapy with Topical Beta-blockers in Patients with Glaucoma or Ocular Hypertension: A 3-Month, Multi-center, Double-masked, Randomized, Vehicle-controlled Trial with Double-masked Extension of Bimatoprost Treatment to 1 Year . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1068.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To evaluate the efficacy and safety of bimatoprost 0.03% as adjunctive therapy with beta-blockers in glaucoma or ocular hypertension patients with high intraocular pressure (IOP) inadequately controlled by beta-blocker monotherapy. Methods:This was a 3 month, multicenter, double-masked, randomized, vehicle-controlled, parallel-group clinical trial with double-masked study extension for active medication to 1 year. For the initial 3 month study, patients with high IOP after at least 2 weeks of beta-blocker monotherapy were randomly assigned to adjunctive treatment with bimatoprost QD (n=93), bimatoprost BID (n=97), or vehicle (n=95). In the 9 month masked extension, patients on bimatoprost continued their regimens, while patients in the vehicle group were randomly assigned to treatment with bimatoprost QD, or BID. IOP and safety were evaluated at prestudy, day 0(baseline), and 4 follow-up visits in each treatment phase. Results:After 3 months of treatment, bimatoprost/beta blocker QD reduced the mean IOP from beta-blocker treated baseline at 8 AM by 7.4 mm Hg (31%). Bimatoprost QD dosing was preffered over BID dosing because it had fewer side effects. When vehicle/beta blocker patients were switched to bimatoprost/beta-blocker, IOP was reduced to levels that were comparable to the continuously treated bimatoprost groups. After one year of treatment, the bimatoprost QD group achieved a mean IOP reduction from baseline at 8 AM of 8 mmHg(33%). The most common side effects were conjunctival hyperemia and growth of eyelashes Conclusion:Bimatoprost QD adjunctive therapy with beta-blockers was safe and effective, providing significant long-term additional IOP lowering in patients inadequately controlled on beta-blocker monotherapy

Keywords: 390 drug toxicity/drug effects • 444 intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×